Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Ultrasonographic diagnosis of demyelinating neuropathy.
Body-worn sensors capture variability, but not decline, of gait and balance measures in multiple sclerosis over 18 months.
Aryl hydrocarbon receptor-mediated induction of the microRNA-132/212 cluster promotes interleukin-17-producing T-helper cell differentiation.
Epidemiology and clinical record of multiple sclerosis in selected countries - a systematic review.
Agent Orange Exposure and Prevalence of Self-reported Diseases in Korean Vietnam Veterans.
Clinical features of patients with Guillain-Barré syndrome at seven hospitals on the East Coast of Australia.
Understanding the neurobiology of CD200 and the CD200 receptor: a therapeutic target for controlling inflammation in human brains?
Body composition and physical function in women with multiple sclerosis.
The MiRNA Journey from Theory to Practice as a CNS Biomarker.
The effect of venous anatomy on the morphology of multiple sclerosis lesions: a susceptibility-weighted imaging study.
[Progressive Multifocal Leukoencephalopathy with Inflammatory Reactions].
Accurate GM atrophy quantification in MS using lesion-filling with co-registered 2D lesion masks.
Monocular and binocular low-contrast visual acuity and optical coherence tomography in pediatric multiple sclerosis.
Understanding disease processes in multiple sclerosis through magnetic resonance imaging studies in animal models.
Preliminary study on the association of AQP4 promoter polymorphism with anti-aquaporin-4 antibody positivity in Southern Han Chinese patients with idiopathic demyelinating disorders of central nervous system.
The benefits and risks of alemtuzumab in multiple sclerosis.
Timed 25-Foot Walk: Direct evidence that improving 20% or greater is clinically meaningful in MS.
Demographic and clinical factors associated with changes in employment in multiple sclerosis.
Longitudinally Extensive Varicella-Zoster Virus Myelitis in a Multiple Sclerosis Patient.
mTORC1 signaling and IL-17 expression: Defining pathways and possible therapeutic targets.
Do Flexible Goal Adjustment and Acceptance Help Preserve Quality of Life in Patients with Multiple Sclerosis?
Differential expression of sema3A and sema7A in a murine model of multiple sclerosis: Implications for a therapeutic design.
[Every fifth case of multiple sclerosis is familial.]
Multiple sclerosis guideline production takes off.
Switching therapies in MS: what are the options?

Pages